Nissen should probably stay out of this. When ASSURE TLD was announced, I felt he way overstepped his position in the trial by stating RVX was barking up the wrong tree even before there was analysis done. In the link below, he had to admit that anaceptrapib might not be safe when Merck discontinued it.

https://www.healio.com/cardiology/chd-prevention/news/online/%7B9b1f9b48-af91-4a81-8e32-a8c465f9d44b%7D/merck-halts-development-of-anacetrapib